KAICO Ltd.
PrivateLast Round
Series B
Apr 15, 2025
Est. Valuation
$18.39M
Total Funding Raised
$10.67M
Company Overview
KAICO Ltd. is a biotechnology company that specializes in developing and manufacturing proteins, vaccines, and diagnostics using a proprietary silkworm-based production platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, D2C Brands, Sports & Fitness
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KAICO Ltd. Comparables
Compare KAICO Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seteka Corporation | 82% | |
| Rimco Co., Ltd. | 81% | |
| 株式会社シルクルネッサンス | 80% |
KAICO Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 15, 2025 | ||||
| Series A Extension | Jan 19, 2024 | ||||
| Series A Extension | Dec 15, 2021 | ||||
| Series A | May 22, 2020 | ||||
| Seed | Oct 1, 2018 |
Key People
Founding team and executive leadership
KAICO Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ITOCHU Technology Ventures | Series A Extension, Series B |
| Mizuho Capital | Series A Extension |
| Higin Capital | Series B |
| 株式会社FFGベンチャービジネスパートナーズ | Series A Extension, Series A, Seed |
| DG Incubation | Series B |
| Tokyo Century | Series A Extension, Series A, Series B |
| 株式会社佐銀キャピタル＆コンサルティング | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 58% MoM.
- Mar 26, 2026
Partnered with Reber Genetics to distribute KAICO Powder in Taiwan.
Recent news
Latest coverage and updates
- attends_eventOct 14, 2026
Kaico Ltd. exhibits at World Vaccine Congress Europe 2026 at RAI Amsterdam in the Netherlands from Oct 19th to 21st '26, presenting its human norovirus vaccine candidate and silkworm-based recombinant protein expression platform.
- attends_eventSep 28, 2026
Kaico Ltd. exhibits at Global Startup EXPO 2026 in Japan on Oct 6th–7th '26
- attends_eventSep 28, 2026
Kaico Ltd. is set to exhibit at Global Startup EXPO 2026 (GSE2026) in Japan on Oct 6th–7th '26
KAICO Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about KAICO Ltd.'s valuation, stock price, and market status.
Is KAICO Ltd. a public or private company?
KAICO Ltd. is a private company.
What is the current stock price of KAICO Ltd.?
KAICO Ltd. is a private company, so its shares have no public market price. Caplight tracks KAICO Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KAICO Ltd. worth (valuation)?
KAICO Ltd.'s valuation is estimated at $18.4M based on funding round data.
Can I buy KAICO Ltd. stock?
KAICO Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KAICO Ltd.'s last funding round?
KAICO Ltd.'s most recent funding round was Series B on April 15, 2025.
Who are the main investors in KAICO Ltd.?
Key investors in KAICO Ltd. include 株式会社FFGベンチャービジネスパートナーズ.
Will KAICO Ltd. IPO soon?
No public IPO plans have been announced for KAICO Ltd..
How can I track KAICO Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in KAICO Ltd.'s shares on secondary markets.